NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors

International Journal of Cancer

Volumn 139, Issue 1, 2016, Pages 171-176

  Yang, Mengmeng ^a   Xu, Xiaoxi ^a   Cai, Jie ^a   Ning, Jinying ^a   Wery, Jean Pierre ^a   Li, Qi Xiang ^a,b  

^a Crown Bioscience Inc   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

EGFR exon 20 insertion; Erbitux; PDX; TKI

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG SENSITIVITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; EXPERIMENTAL MODEL; GENE INSERTION; GENE INSERTION SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NON SMALL CELL LUNG CANCER; PRIMARY CELL LINE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXONS; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961635278     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30047     Document Type: Article

References (24)

1. Yasuda H, Kobayashi S, Costa DB., EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012; 13: e23-31.
2. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
3. Tseng JS, Yang TY, Chen KC, et al., Retrospective study of erlotinib in patients with advanced squamous lung cancer. Lung Cancer 2012; 77: 128-33.
4. Sequist LV, Soria JC, Goldman JW, et al., Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372: 1700-9.
5. Walter AO, Sjin RT, Haringsma HJ, et al., Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-15.
6. Ciardiello F, Tortora G., EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
7. Yang M, Shan B, Li Q, et al., Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients. Int J Cancer 2013; 132: E74-84.
8. Brand TM, Iida M, Wheeler DL., Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011; 11: 777-92.
9. Yasuda H, Park E, Yun CH, et al., Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013; 5: 216ra177.
10. Ding L, Ellis MJ, Li S, et al., Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
11. Marangoni E, Vincent-Salomon A, Auger N, et al., A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13: 3989-98.
12. Nemati F, Sastre-Garau X, Laurent C, et al., Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010; 16: 2352-62.
13. Nemati F, Daniel C, Arvelo F, et al., Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anticancer Drugs 2010; 21: 25-32.
14. Fichtner I, Rolff J, Soong R, et al., Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-68.
15. Hennessey PT, Ochs MF, Mydlarz WW, et al., Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 2011; 6: e20584.
16. Chen D, Huang X, Cai J, et al., A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. Oncotarget 2015; 6: 40815-21.
17. Jiang J, Wang DD, Yang M, et al., Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model. Oncotarget 2015; 6: 15639-51.
18. Zhang L, Yang J, Cai J, et al., A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep 2013; 3: 2992.
19. Bria E, Pilotto S, Amato E, et al., Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. Oncotarget 2015; 6: 12783-95.
20. Tsigelny IF, Wheler JJ, Greenberg JP, et al., Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget 2015; 6: 6029-39.
21. Williams KJ, Telfer BA, Stratford IJ, et al., ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86: 1157-61.
22. Furugaki K, Iwai T, Kondoh K, et al., Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncol Lett 2010; 1: 231-35.
23. Gao SP, Mark KG, Leslie K, et al., Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-56.
24. Gao H, Korn JM, Ferretti S, et al., High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 2015; 21: 1318-25.